Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

INK-128

HY-13328

(Sapanisertib; MLN0128)

INK-128

INK-128 Chemical Structure

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $88 In-stock
5 mg $80 In-stock
10 mg $100 In-stock
50 mg $250 In-stock
100 mg $450 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €86 In-stock
5 mg €78 In-stock
10 mg €98 In-stock
50 mg €245 In-stock
100 mg €441 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: INK-128
Cat. No.: HY-13328

INK-128 Data Sheet

  • View current batch:

    Purity: 99.55%

  • Pdf Version Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Customer View

Related Compound Libraries

Biological Activity of INK-128

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.
IC50 value: 1 nM [1]
Target: mTOR
in vitro: INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases [1]. As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors [2].
in vivo: In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. [1] Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models [2].

Chemical Information

M.Wt 309.33 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C15H15N7O
CAS No 1224844-38-5
Solvent & Solubility

DMSO 62 mg/ml; Water <1 mg/ml

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.2328 mL 16.1640 mL 32.3279 mL
5 mM 0.6466 mL 3.2328 mL 6.4656 mL
10 mM 0.3233 mL 1.6164 mL 3.2328 mL

Clinical Information of INK-128

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
INK-128 Millennium Pharmaceuticals Inc Non-Hodgkin lymphoma 30-NOV-10 31-JAN-14 Phase 1 05-AUG-13
Millennium Pharmaceuticals Inc Macroglobulinemia 30-NOV-10 31-JAN-14 Phase 1 05-AUG-13
Millennium Pharmaceuticals Inc Advanced solid tumor 31-JUL-13 30-NOV-16 Phase 1 12-SEP-13
Millennium Pharmaceuticals Inc Advanced solid tumor 31-JAN-10 31-MAR-15 Phase 1 25-JUL-13
Millennium Pharmaceuticals Inc Advanced solid tumor 31-MAR-11 28-FEB-14 Phase 1 20-NOV-13
Millennium Pharmaceuticals Inc Multiple myeloma 30-NOV-10 31-JAN-14 Phase 1 05-AUG-13

References on INK-128

Inhibitor Kit

Related mTOR Products

  • AZD-8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (~1,000-fold) against PI3K isoforms and ATM/DNA-PK.

  • AZD2014

    AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms ((alpha)/(beta)/(gamma)/(delta)).

  • CC-223

    CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K(alpha) (IC50=4 (mu)M).

  • Deforolimus

    Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.

  • ETP-46464

    ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-K(alpha), and ATM (IC50= 0.6, 14, 36, 170, and 545 nM, respectively).

  • Everolimus

    Everolimus (RAD001) is a mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.

  • GDC-0349

    GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3K(alpha) and other 266 kinases.

  • GDC-0980

    GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3K(alpha)/(beta)/(delta)/(gamma) with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively; also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases.

  • GNE-317

    GNE-317 is a potent PI3K/mTOR inhibitor that can cross the blood–brain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.

  • GNE-477

    GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3K(alpha), Kiapp is 21 nM for mTOR.

MORE